Testing effectiveness (Phase 2)UnknownNCT03177239
What this trial is testing
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
Who this might be right for
Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 1Papillary Renal Cell Carcinoma Type 2+3 more
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 85